NeuroPace (NPCE) Common Equity (2020 - 2026)

NeuroPace's Common Equity history runs 7 years deep, the most recent figure standing at $14.5 million for Q1 2026.

• In Q1 2026, Common Equity fell 40.44% year-over-year to $14.5 million; the TTM figure through Mar 2026 stood at $14.5 million (down 40.44% YoY), while the FY2025 annual figure was $19.0 million, up 137.5% from the prior year.
• Common Equity was $14.5 million for Q1 2026 at NeuroPace, down from $19.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $62.8 million in Q1 2022 to a low of $8.0 million in Q4 2024.
• Historically, Common Equity has averaged $24.6 million across 5 years, with a median of $19.4 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Common Equity soared 140.16% in 2022, then slumped 62.31% in 2023.
• A 5-year view of Common Equity shows it stood at $34.8 million in 2022, then plunged by 40.61% to $20.7 million in 2023, then sank by 61.2% to $8.0 million in 2024, then soared by 137.5% to $19.0 million in 2025, then fell by 24.05% to $14.5 million in 2026.
• The last three Common Equity figures came in at $14.5 million (Q1 2026), $19.0 million (Q4 2025), and $18.5 million (Q3 2025), per Business Quant data.